MAPT and Huntington disease: More recently, in collaboration with David Rubinsztein and coworkers (Cambridge Institute of Medical Research), using zebrafish models of Alzheimer’s and Huntington’s disease, we showed that rolipram also promotes the clearance of two different disease-associated tau mutants and a mutant huntingtin exon 1 containing a 71-polyglutamine expansion [16].